Post-market surveillance data demonstrate high mortality associated with enfortumab vedotin skin toxicity, not worsened by immune checkpoint inhibitors or corticosteroids.

HOME
>
論文・技術情報
>
Post-market surveillance data demonstrate high mortality associated with enfortumab vedotin skin toxicity, not worsened by immune checkpoint inhibitors or corticosteroids.

アブストラクト
ジャーナル名	Journal of the American Academy of Dermatology
Pubmed追加日	2025/11/4
投稿者	Kilton, Mackenzie M; Wei, Erin X; Georgeson, Corey J; Hirner, Jesse P
組織名	University of Nebraska College of Medicine, Omaha, Nebraska.;University of Nebraska College of Medicine, Omaha, Nebraska; Department of;Dermatology, University of Nebraska Medical Center, Omaha, Nebraska.;Dermatology, University of Nebraska Medical Center, Omaha, Nebraska. Electronic;address: jhirner@unmc.edu.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/41183712/